About better therapeutics inc - BTTX
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. It offers software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.
BTTX At a Glance
Better Therapeutics, Inc.
548 Market Street
San Francisco, California 94104
| Phone | 1-415-887-2311 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -39,760,000.00 | |
| Sector | Health Technology | Employees | 54 | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
BTTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.708 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.591 |
BTTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -736,296.296 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BTTX Liquidity
| Current Ratio | 1.367 |
| Quick Ratio | 1.367 |
| Cash Ratio | 1.166 |
BTTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -107.603 |
| Return on Equity | -221.993 |
| Return on Total Capital | -284.386 |
| Return on Invested Capital | -142.831 |
BTTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 106.43 |
| Total Debt to Total Assets | 64.856 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 74.015 |